{
  "nctId": "NCT01958281",
  "briefTitle": "Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency",
  "officialTitle": "A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 Weeks in Genotype 1 or 4 HCV Infected Subjects With Renal Insufficiency",
  "protocolDocument": {
    "nctId": "NCT01958281",
    "filename": "Prot_004.pdf",
    "label": "Study Protocol: Amendment 4",
    "date": "2015-04-23",
    "uploadDate": "2018-06-18T20:45",
    "size": 2391102,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01958281/document/Prot_004.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "SEQUENTIAL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 38,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-10-07",
    "completionDate": "2017-10-19",
    "primaryCompletionDate": "2017-07-18",
    "firstSubmitDate": "2013-10-06",
    "firstPostDate": "2013-10-09"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Cohorts 1 and 2: chronic genotype 1 or 3 HCV infection\n* Cohort 3: chronic genotype 1 or 4 HCV infection\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* Screening labs within defined thresholds\n* Cirrhosis determination at screening\n\nKey Exclusion Criteria:\n\n* Females who are pregnant or nursing or males who have a pregnant partner\n* Prior null response to pegylated interferon (Peg-IFN)+RBV therapy (Cohorts 1 and 2) or for individuals with cirrhosis, prior treatment failure with IFN-based therapy not resulting from treatment intolerance (Cohort 3)\n* Current of prior history of hepatic decompensation\n* Infection with hepatitis B virus (HBV) or HIV\n* History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with individual's treatment and/or adherence to the protocol\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)",
        "description": "SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.",
        "timeFrame": "Posttreatment Week 12"
      },
      {
        "measure": "Percentage of Participants Experiencing Treatment-Emergent Adverse Events",
        "timeFrame": "Up to 24 weeks plus 30 days"
      },
      {
        "measure": "Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities",
        "description": "Treatment-emergent laboratory abnormalities were defined as values that increased by at least 1 toxicity grade from baseline at any time postbaseline up to the date of last dose of study drug plus 30 days.",
        "timeFrame": "Up to 24 weeks plus 30 days"
      },
      {
        "measure": "Percentage of Participants Experiencing Clinically Significant 12-lead Electrocardiogram (ECG) Abnormalities",
        "timeFrame": "Up to 24 weeks plus 30 days"
      },
      {
        "measure": "Percentage of Participants Experiencing Treatment-Emergent Adverse Events Associated With Vital Sign Abnormalities",
        "timeFrame": "Up to 24 weeks plus 30 days"
      },
      {
        "measure": "Pharmacokinetic (PK) Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "Cmax is defined as the maximum concentration of drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "Cmax is defined as the maximum concentration of drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "Cmax is defined as the maximum concentration of drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)",
        "description": "SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping study treatment.",
        "timeFrame": "Posttreatment Week 4"
      },
      {
        "measure": "Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)",
        "description": "SVR4 was defined as HCV RNA \\< LLOQ at 24 weeks after stopping study treatment.",
        "timeFrame": "Posttreatment Week 24"
      },
      {
        "measure": "Percentage of Participants With Overall Virologic Failure",
        "description": "Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.",
        "timeFrame": "Up to Posttreatment Week 24"
      },
      {
        "measure": "PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "AUClast is defined as the concentration of drug from time zero to the last observable concentration.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "AUClast is defined as the concentration of drug from time zero to the last observable concentration.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "AUClast is defined as the concentration of drug from time zero to the last observable concentration.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "Clast is defined as the last observable concentration of drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "Clast is defined as the last observable concentration of drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "Clast is defined as the last observable concentration of drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "Tmax is defined as the time (observed time point) of Cmax.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "Tmax is defined as the time (observed time point) of Cmax.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "Tmax is defined as the time (observed time point) of Cmax.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "Tlast is defined as the time (observed time point) of Clast.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "Tlast is defined as the time (observed time point) of Clast.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "Tlast is defined as the time (observed time point) of Clast.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      },
      {
        "measure": "PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)",
        "description": "t1/2 is defined as the estimate of the terminal elimination half-life of the drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2"
      },
      {
        "measure": "PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)",
        "description": "t1/2 is defined as the estimate of the terminal elimination half-life of the drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 12"
      },
      {
        "measure": "PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)",
        "description": "t1/2 is defined as the estimate of the terminal elimination half-life of the drug.",
        "timeFrame": "Predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdose at Week 2 or 4"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 14,
      "secondaryCount": 21,
      "otherCount": 0,
      "totalCount": 35
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SEQUENTIAL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:25.762Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}